Table 1 Baseline Characteristics of Study Participants
From: DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database
Characteristics | Number |
|---|---|
Age(y), median(range) | 7.6 (1–18) |
Age group, years | |
≥ 1, < 10 | 951 (57.0%) |
≥ 10 | 717 (43.0%) |
Gender, n(%) | |
Male | 993 (59.5%) |
Female | 675 (40.5%) |
Race, n(%) | |
White | 1246 (74.7%) |
Non-white | 422 (25.3%) |
WBC(×109/L), median(range) | 33.7 (0.4–1306.0) |
WBC group, ×109/L | |
< 50 | 956 (57.3%) |
≥ 50 | 712 (42.7%) |
Immunophenotype, n(%) | |
B-Precursor | 721 (43.2%) |
B Cell ALL | 497 (29.8%) |
T Cell ALL | 242 (14.5%) |
B precursor (Non-T, Non-B ALL) | 208 (12.5%) |
DI, median(range) | 1.0 (0.51–1.9) |
Karyotype, n(%) | |
Normal | 739 (44.3%) |
hypodiploidy | 98 (5.9%) |
hyperdiploid | 395 (23.7%) |
NA | 436 (26.1%) |
Fusion gene, n(%) | |
ETV6/RUNX1 | 213 (12.8%) |
MLL | 56 (3.4%) |
TCF3/PBX1 | 92 (5.5%) |
BCR/ABL1 | 41 (2.5%) |
Negative | 905 (54.3%) |
Unknown | 361 (21.6%) |
CNS status, n(%) | |
CNS1 | 1353 (81.1%) |
CNS2 | 245 (14.7%) |
CNS3 | 70 (4.2%) |
Prednisone response, n(%) | |
Good | 1154 (69.2%) |
Poor | 514 (30.8%) |
BM blasts on Day+ 29, n(%) | |
CR | 1625 (97.4%) |
NR | 43 (2.6%) |
BM relapse, n(%) | |
No | 1359 (81.5%) |
Yes | 309 (18.5%) |
CNS relapse, n(%) | |
No | 1555 (93.2%) |
Yes | 113 (6.8%) |
Testes site of relapse, n(%) | |
No | 1657 (99.3%) |
Yes | 11 (0.7%) |
Chemotherapy protocol, n(%) | |
9906 | 222 (13.3%) |
AALL0232 | 789 (47.3%) |
AALL0331 | 415 (24.9%) |
AALL0434 | 242 (14.5%) |